Triptorelin is a gonadotropin-releasing hormone analogue that has been used in the clinical setting to treat advanced prostate cancer as part of a multi-faceted approach to androgen deprivation therapy. Similar to luteinizing hormone-releasing hormone, triptorelin is a potent inhibitor of testosterone and estrogen synthesis when given in long-term, continuous dosing. In the UK, triptorelin is used to suppress testosterone and estrogen synthesis in transgender people. The peptide has also found application in the treatment of hormone-receptor-positive breast cancer in premenopausal women.